← Every applicant
Long Grove Pharms FDA Approvals
9 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| DALBAVANCIN HYDROCHLORIDENew drugFeb 26, 2026POWDER, INTRAVENOUS |
| DIAZEPAMNew drugDec 31, 2024INJECTABLE, INJECTION |
| ERIBULIN MESYLATENew drugJul 18, 2024SOLUTION, INTRAVENOUS |
| VASOPRESSIN IN SODIUM CHLORIDE 0.9%New drugJul 11, 2024SOLUTION, INTRAVENOUS |
| EDARAVONENew drugMay 6, 2024SOLUTION, INTRAVENOUS |
| SODIUM BICARBONATENew drugFeb 27, 2024SOLUTION, INTRAVENOUS |
| NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDENew drugOct 6, 2022SOLUTION, INTRAVENOUS |
| CARBOPROST TROMETHAMINENew drugAug 9, 2022INJECTABLE, INJECTION |
| TRIAMCINOLONE ACETONIDENew drugJan 19, 2022INJECTABLE, INJECTION |